Evaluation of Ascorbate-Meglumine Therapeutic for SRS

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

May 17, 2025

Study Completion Date

September 9, 2025

Conditions
Safety
Interventions
DRUG

Ascorbate-Meglumine

Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection

Trial Locations (1)

27709

Duke Health, Durham

Sponsors
All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

lead

LadeRx LLC

INDUSTRY

NCT06433791 - Evaluation of Ascorbate-Meglumine Therapeutic for SRS | Biotech Hunter | Biotech Hunter